Clinical Core

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 7U19AI168632-02

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2022
    2027
  • Known Financial Commitments (USD)

    $318,447
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    Asuncion Mejias
  • Research Location

    United States of America
  • Lead Research Institution

    ST. JUDE CHILDREN'S RESEARCH HOSPITAL
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Infants (1 month to 1 year)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Clinical Core Principal Investigator: Asuncion Mejias, M.D. Abstract This Core will serve three main goals. First, by enrolling all patients, obtaining the human samples, and collecting the clinical data it will simplify sample organization, data management and compliance with all regulatory aspects of the U19. In addition, the Clinical Core will support Projects 1 and 2, by performing the viral PCR assays, which will improve analytical performance and efficiency; and the Data Management Core, by coordinating and sharing de-identified clinical data. Specifically, the Core will be responsible for: 1) enrolling infants in the first 6 months of life with influenza or SARS-CoV-2 infection, as well as healthy non-infected controls, and obtaining sequential blood and respiratory samples pre and post influenza and COVID-19 vaccination during the first 3 years of life; 2) sample organization and distribution between Projects (1 and 2); 3) longitudinal clinical data collection, data curation and data transfer to the Data Management Core for data analyses and integration with all immune assays; 4) measure influenza and SARS-CoV-2 viral loads by quantitative real-time PCR in clinical samples (nasopharyngeal swabs) from infants with influenza or SARS-CoV-2 infection. This approach will optimize the use of resources and will facilitate integration and synergy among all projects.